Back to search results

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Abroad (travel likely)RecruitingPHASE3

Conditions

Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Summit Medical Group Oncology, Berkeley Heights, New Jersey, United States

    Contact: Study coordinator (Michelle Mackenzie) · mmackenzie@summithealth.com · 973-436-1755
    Contact: Principal Investigator (Lalitha Anand)

  • The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Hannah Davis) · Hannah.Davis@osumc.edu
    Contact: Principal Investigator (Andrew Srisuwananukorn)

  • Novartis Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina

  • Novartis Investigative Site, Capital Federal, Argentina

  • Novartis Investigative Site, Clayton, Victoria, Australia

  • Novartis Investigative Site, Hefei, Anhui, China

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Nantong, Jiangsu, China

  • Novartis Investigative Site, Yantai, Shandong, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Chongqing, China

  • Novartis Investigative Site, Fuzhou, China

  • Novartis Investigative Site, Shenyang, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Pune, Maharashtra, India

  • Novartis Investigative Site, Kolkata, West Bengal, India

  • Novartis Investigative Site, Johor Bahru, Malaysia

  • Novartis Investigative Site, Kuala Selangor, Malaysia

  • Novartis Investigative Site, Suwon, Gyeonggi-do, South Korea

  • Novartis Investigative Site, Jeonju, Jeollabuk-do, South Korea

  • Novartis Investigative Site, Seoul, Yangcheon Gu, South Korea

  • Novartis Investigative Site, Busan, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Basel, Switzerland

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Genolier, Switzerland

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)